Collplant Biotechnologies Ltd expected to post a loss of 14 cents a share - Earnings Preview

Reuters

Aug 18

<a href="https://laohu8.com/S/CLGN">Collplant Biotechnologies</a> Ltd <clgn.oq> expected to post a loss of 14 cents a share - Earnings Preview </clgn.oq>

Collplant Biotechnologies Ltd CLGN.OQ, CLGN.O is expected to show a rise in quarterly revenue when it reports results on August 20 for the period ending June 30 2025
The Rehovot Israel-based company is expected to report a 921.7% increase in revenue to $2.544 million from $249 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Collplant Biotechnologies Ltd is for a loss of 14 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $12.00, about 78.8% above its last closing price of $2.55

This summary was machine generated August 18 at 12:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560761907"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560761907\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560761907?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560761907","market":"fut","top_or_hot":-1,"title":"Collplant Biotechnologies Ltd  expected to post a loss of 14 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> Ltd <clgn.oq> expected to post a loss of 14 cents a share - Earnings Preview </clgn.oq></title></head><body><ul><li><p>Collplant Biotechnologies Ltd <span>CLGN.OQ</span>, <span>CLGN.O</span> is expected to  show a rise in quarterly revenue when it reports  results on August 20 for the period ending June 30 2025</p></li><li><p>The Rehovot Israel-based   company is expected to report a 921.7% increase in revenue to $2.544 million from $249 thousand a year ago, according to the estimate from one analyst, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Collplant Biotechnologies Ltd is for a loss of 14 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $12.00, about 78.8% above its last closing price of $2.55</p></li></ul><p>This summary was machine generated August 18 at 12:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Collplant Biotechnologies Ltd  expected to post a loss of 14 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollplant Biotechnologies Ltd  expected to post a loss of 14 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-18 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> Ltd <clgn.oq> expected to post a loss of 14 cents a share - Earnings Preview </clgn.oq></title></head><body><ul><li><p>Collplant Biotechnologies Ltd <span>CLGN.OQ</span>, <span>CLGN.O</span> is expected to  show a rise in quarterly revenue when it reports  results on August 20 for the period ending June 30 2025</p></li><li><p>The Rehovot Israel-based   company is expected to report a 921.7% increase in revenue to $2.544 million from $249 thousand a year ago, according to the estimate from one analyst, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Collplant Biotechnologies Ltd is for a loss of 14 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $12.00, about 78.8% above its last closing price of $2.55</p></li></ul><p>This summary was machine generated August 18 at 12:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLGN","symbol_name":"COLLPLANT BIOTECHNOLOGIES LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nL8N3UA0KA:1","article_id":"2560761907","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560761907","pubTimestamp":1755520506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Collplant Biotechnologies Ltd  expected to post a loss of14cents a share - Earnings Preview Collplant Biotechnologies Ltd CLGN.OQ, CLGN.O is expected to  show a rise in quarterly revenue when it repor","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CLGN":"COLLPLANT BIOTECHNOLOGIES LTD"},"translate_title":"Collplant Biotechnologies Ltd预计每股亏损14美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLGN":0.9},"content_text":"Collplant Biotechnologies Ltd  expected to post a loss of 14 cents a share - Earnings Preview Collplant Biotechnologies Ltd CLGN.OQ, CLGN.O is expected to  show a rise in quarterly revenue when it reports  results on August 20 for the period ending June 30 2025The Rehovot Israel-based   company is expected to report a 921.7% increase in revenue to $2.544 million from $249 thousand a year ago, according to the estimate from one analyst, based on LSEG data.LSEG's mean analyst estimate for Collplant Biotechnologies Ltd is for a loss of 14 cents per share. The one available analyst rating on the shares is \"buy\".  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $12.00, about 78.8% above its last closing price of $2.55This summary was machine generated August 18 at 12:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}